 |
|
Are Cyclooxygenase-2 Inhibitors Being Taken Only by Those Who Need Them?
Arch Intern Med. 2005;165:1066-1067.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Cyclooxygenase-2 (COX-2) inhibitors were developed in response to the tendency of nonsteroidal anti-inflammatory drugs (NSAIDs) to cause gastrointestinal bleeding.1 Concerns about cardiovascular safety were raised about rofecoxib in an early clinical trial; this drug was recently withdrawn after it was shown to increase the risk of myocardial infarction in a long-term cancer prevention trial. Similar concerns have arisen with valdecoxib and celecoxib. In the controversy surrounding these drugs,2 an important question is how much they have been used by individuals at low risk of gastrointestinal complications who might safely take traditional NSAIDs. We have explored this in a US population–based survey of medication use.
Methods
The Slone Survey has been conducted continuously since February 1998.3 Households in the 48 contiguous states and the District of Columbia are identified by random-digit dialing. One individual in each household is randomly selected for interview. Information is obtained on demographic details and the use of . . . [Full Text of this Article]
Results
Comment
AUTHOR INFORMATION
David W. Kaufman, ScD;
Judith P. Kelly, MS;
Lynn Rosenberg, ScD;
Theresa E. Anderson, RN;
Allen A. Mitchell, MD
RELATED ARTICLE
Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study
Søren P. Johnsen, Heidi Larsson, Robert E. Tarone, Joseph K. McLaughlin, Bente Nørgård, Søren Friis, and Henrik T. Sørensen
Arch Intern Med. 2005;165(9):978-984.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
Chaiamnuay et al.
Am J Health Syst Pharm 2006;63:1837-1851.
ABSTRACT
| FULL TEXT
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman et al.
Circulation 2005;112:759-770.
FULL TEXT
|
